Precious Metals

[gfp927z]

>>> AXSM upgraded...

https://thefly.com/news.php?symbol=AXSM

Axsome Therapeutics initiated at SunTrust Axsome Therapeutics initiated with a Buy at SunTrust. SunTrust analyst Joon Lee initiated Axsome Therapeutics with a Buy rating and a price target of $50, saying that although the stock has multiplied about 10-times year-to-date, it remains "significantly undervalued". The analyst cites the company's AXS-05 lead asset having been "de-risked" by the incoming data and is positive on its opportunity in Major Depressive Disorder, Treatment Resistant Depression, and Alzheimer's Disease Agitation. For the latter, Lee says AXS-05 has the potential to be a "best-in-class drug", while also taking large market share in the other two conditions if approved. The analyst adds that the upcoming 5 mid-to-late stage clinical readouts over the next 12-18 months should generate more shareholder value for Axsome Therapeutics.

Read more at:
https://thefly.com/landingPageNews.php?id=2914221

Axsome Therapeutics analyst commentary at Cantor Fitzgerald Axsome Therapeutics price target raised to $35 from $25 at Cantor Fitzgerald. Cantor Fitzgerald analyst Charles Duncan raised his price target for Axsome Therapeutics to $35 from $25 and reiterates an Overweight rating on the shares. The analyst says his discussions with key opinion leaders at the American Psychiatric Association conference enhanced his conviction on the company's path forward in depression. He sees an "asymmetric" reward/risk scenario, despite the move in the stock already in 2019, heading into expected top line Phase 3 data from the Stride-1 trial.

Read more at:
https://thefly.com/landingPageNews.php?id=2914261

Axsome Therapeutics analyst commentary at H.C. Wainwright Axsome Therapeutics price target raised to $30 from $23 at H.C. Wainwright. H.C. Wainwright analyst Raghuram Selvaraju raised his price target for Axsome Therapeutics to $30 from $23 saying the company recently announced several key positive developments with multiple candidates in its pipeline. The analyst highlights the clarification of a regulatory path forward for AXS-05 in depression, which he believes could culminate in a new drug application filing in 2020. Selvaraju increased his probability of approval for AXS-05 in treatment-resistant depression to 50% from 40% and reiterates a Buy rating on Axsome Therapeutics.

Read more at:
https://thefly.com/landingPageNews.php?id=2913105

<<<


https://investorshub.advfn.com/boards/read_msg.aspx?message_id=149060068